What is a lentiginous compound nevus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is a Lentiginous Compound Nevus?

A lentiginous compound nevus is a benign melanocytic lesion characterized by a specific histopathologic pattern where melanocytes proliferate both at the dermoepidermal junction (junctional component) and within the dermis (dermal component), with a distinctive lentiginous growth pattern showing elongated rete ridges and continuous melanocyte proliferation along the basal layer.

Histopathologic Features

The defining microscopic characteristics include:

  • Junctional component: Continuous proliferation of melanocytes at the dermoepidermal junction with elongation of rete ridges 1
  • Dermal component: Presence of nevus cells (melanocytes) within the dermis, establishing the "compound" nature
  • Lentiginous pattern: Single scattered melanocytes or small clusters distributed along the basal layer, sometimes extending into the upper epidermis 1
  • Melanocyte morphology: Cells typically have abundant pale cytoplasm with round to oval nuclei, occasionally hyperchromatic with prominent nucleoli 1

Clinical Presentation

These lesions can present in various forms:

  • May appear as flat to slightly raised pigmented lesions
  • Can occur as part of speckled lentiginous nevus (nevus spilus), where darker speckles overlay a tan background 2, 3
  • The lentiginous pattern can be seen in acral locations (palms/soles) as acral-lentiginous nevi 1

Important Diagnostic Distinctions

Critical pitfall: Lentiginous compound nevi can histologically mimic melanoma, particularly:

  • Lentigo maligna melanoma: The lentiginous pattern with melanocyte atypia can be confused with early melanoma 4
  • Acral lentiginous melanoma: When occurring on acral sites, these benign nevi share architectural features with their malignant counterpart 1

Key features distinguishing benign lentiginous compound nevi from melanoma 1:

  • Absence of pagetoid lateral spread of melanocytes
  • No mitotic activity in the deep dermal component
  • Evidence of dermal nevocytic maturation (smaller cells deeper in dermis)
  • Lack of significant cytological atypia
  • Absence of well-formed lamellar fibroplasia

Clinical Management

For typical lentiginous compound nevi: Observation is appropriate for stable, clinically benign-appearing lesions. Excision is indicated when:

  • Clinical features suggest melanoma (ABCD criteria: Asymmetry, Border irregularity, Color heterogeneity, Dynamics/change) 5, 6
  • Dermoscopic examination reveals concerning features
  • The lesion is changing or symptomatic

When excision is performed: Complete excision with narrow margins (typically 2-5mm) is sufficient for benign lesions to ensure complete removal and allow full histopathologic assessment 5.

Special Considerations

Atypical lentiginous nevi: Some lentiginous compound nevi may show moderate cytological atypia (atypical lentiginous nevus), which can further complicate diagnosis 4. These lesions typically show low Ki-67 proliferation index (<5%) and behave benignly, but require careful histopathologic evaluation to exclude melanoma.

In acral locations: Poor lateral circumscription is a normal feature of acral-lentiginous nevi and should not automatically raise concern for malignancy 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.